Abstract
Corticosteroids form the mainstay of therapy for noninfectious uveitis. The anti-inflammatory and immunosuppressive action is mediated by controlling the protein synthesis both at cellular and molecular level. Corticosteroids in uveitis can be administered by topical, periocular, intravitreal, and oral routes. Long-term use of corticosteroids is associated with side effects such as hypertension, osteoporosis, hyperglycemia, Cushing’s syndrome, cataract, glaucoma, and others. Corticosteroid-sparing immunosuppressive agents form the next line of treatment in chronic, recurrent, and nonresponsive uveitis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fauci AS. Clinical aspects of immunosuppression: use of cytotoxic agents and corticosteroids. Immunology. Philadelphia: WB Saunders; 1978.
Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: fundamentals and clinical practice. St. Louis: Mosby; 1996.
McGhee CN. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992;76:681–4.
Leopold IH, Maylath R. Intraocular penetration of cortisone and its effectiveness against experimental corneal burns. Am J Ophthalmol. 1952;42:1125–34.
Schoenwald RD, Stewart P. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J Pharm Sci. 1980;69:391–4.
Awan MA, Agarwal PK, Watson DG, McGhee CN. Dutton. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93:708–13.
Foster CS, Davanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26:475–83.
Nozik RA. Periocular injection of steroids. Trans Am Acad Ophth Otol. 1976;76:695–704.
Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995;120:55–64.
Salek SS, Leder HA, Butler NJ, Gan TJ, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm. 2013;21(4):257–63.
Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681–6.
Habot-Wilner Z, Sallam A, Pacheco PA, Do HH, McCluskey P, Lightman S. Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur J Ophthalmol. 2011;21 Suppl 6:S56–61.
Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147:1048–54.
Lowder C, Belfort Jr R, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM, Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–53.
Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T, Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–7.
Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (retisert) and dexamethasone (ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29:501–7.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916–26.
Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436–41.
Slabaugh MA, Herlihy E, Ongchin S, van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol. 2012;153:932–8.
Say EA, Shields CL, Bianciotto C, Shields JA. Perilymphatic subcutaneous fat atrophy and cutaneous depigmentation after periocular triamcinolone acetonide injection in a child. J AAPOS. 2011;15:107–8.
Jonas JB, Kamppeter BA. Intravitreal triamcinolone acetonide and central serous chorioretinopathy. Br J Ophthalmol. 2005;89:386–7.
Malclès A, Janin-Manificat H, Yhuel Y, Russo A, Agard E, El Chehab H, Ract Madoux G, Masse H, Burillon C, Dot C. Anterior chamber migration of intravitreal dexamethasone implant (Ozurdex®) in pseudophakic eyes: report of three cases. J Fr Ophtalmol. 2013;36:362–7.
Bansal R, Bansal P, Kulkarni P, Gupta V, Sharma A, Gupta A. Wandering Ozurdex(®) implant. J Ophthalmic Inflamm Infect. 2012;2:1–5.
Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol. 2007;143:334–5.
Ramaiya KJ, Rao PK. Herpetic necrotizing retinitis following fluocinolone acetonide intravitreal implant. Ocul Immunol Inflamm. 2011;19:72–4.
Sims JL, Chee SP. Cytomegalovirus endotheliitis following fluocinolone acetonide (Retisert) implant. Eye. 2010;24:197–8.
Rofagha S, Prechanond T, Stewart JM. Late spontaneous dissociation of a fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm. 2013;21:62–3.
Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer India
About this chapter
Cite this chapter
Agarwal, M. (2016). Corticosteroid in Uveitis. In: Biswas, J., Majumder, P. (eds) Uveitis: An Update. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2295-8_5
Download citation
DOI: https://doi.org/10.1007/978-81-322-2295-8_5
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-2294-1
Online ISBN: 978-81-322-2295-8
eBook Packages: MedicineMedicine (R0)